{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T10:23:37Z","timestamp":1648895017752},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00393-018-0533-3","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T09:29:24Z","timestamp":1536571764000},"page":"808-814","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stellenwert der Kombination von Biologika mit Methotrexat in der Behandlung der Psoriasisarthritis\u00a0\u2013 Fragen bleiben offen"],"prefix":"10.1007","volume":"77","author":[{"given":"S.","family":"Dauth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"K\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Rossmanith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"533_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2015","unstructured":"Gossec L, Smolen JS, Ramiro S et\u00a0al (2015) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499\u2013510","journal-title":"Ann Rheum Dis"},{"key":"533_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2015","unstructured":"Singh JA, Saag KG, Bridges SL Jr. et\u00a0al (2015) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68:1\u201325","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"533_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis. Arthritis Rheum 54:26\u201337 (who had not had previous methotrexate treatment)","journal-title":"Arthritis Rheum"},{"key":"533_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","volume":"53","author":"M Jani","year":"2014","unstructured":"Jani M, Barton A, Warren RB et\u00a0al (2014) The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxf) 53:213\u2013222","journal-title":"Rheumatology (Oxf.)"},{"key":"533_CR5","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3899\/jrheum.140876","volume":"41","author":"ML Acosta Felquer","year":"2014","unstructured":"Acosta Felquer ML, Coates LC, Soriano ER et\u00a0al (2014) Drug therapies for peripheral joint disease in psoriatic arthritis: a\u00a0systematic review. J\u00a0Rheumatol 41:2277\u20132285","journal-title":"J Rheumatol"},{"key":"533_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","volume":"73","author":"KM Fagerli","year":"2014","unstructured":"Fagerli KM, Lie E, Van Der Heijde D et al (2014) The role of methotrexate co-medication in TNF inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR DMARD study. Ann Rheum Dis 73:132\u2013137","journal-title":"Ann Rheum Dis"},{"key":"533_CR7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/ard.2007.073544","volume":"67","author":"LE Kristensen","year":"2008","unstructured":"Kristensen LE, Gulfe A, Saxne T et al (2008) Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 67:364\u2013369","journal-title":"Ann Rheum Dis"},{"key":"533_CR8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B et\u00a0al (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227\u20131236","journal-title":"Arthritis Rheum"},{"key":"533_CR9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/ard.2005.045658","volume":"65","author":"A Kavanaugh","year":"2006","unstructured":"Kavanaugh A, Antoni CE, Gladman D et\u00a0al (2006) The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 65:1038\u20131043","journal-title":"Ann Rheum Dis"},{"key":"533_CR10","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a\u00a0double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:3279\u20133289","journal-title":"Arthritis Rheum"},{"key":"533_CR11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/art.22379","volume":"56","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Ritchlin CT et al (2007) Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 56:476\u2013488","journal-title":"Arthritis Rheum"},{"key":"533_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3899\/jrheum.141596","volume":"43","author":"F Behrens","year":"2016","unstructured":"Behrens F, Koehm M, Arndt U et\u00a0al (2016) Does concomitant methotrexate with adalimumab influence treatment outcomes in patients with psoriatic arthritis? Data from a\u00a0large observational study. J\u00a0Rheumatol 43:632\u2013639","journal-title":"J Rheumatol"},{"key":"533_CR13","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3899\/jrheum.151290","volume":"43","author":"B Combe","year":"2016","unstructured":"Combe B, Behrens F, Mchugh N et\u00a0al (2016) Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials. J\u00a0Rheumatol 43:1063\u20131067","journal-title":"J Rheumatol"},{"key":"533_CR14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170932","author":"F Behrens","year":"2018","unstructured":"Behrens F, Meier L, Prinz JC et al (2018) Simultaneous response in several domains in patients with psoriatic disease treated with etanercept as monotherapy or in combination with conventional synthetic disease-modifying Antirheumatic drugs. J\u00a0Rheumatol. \n                    https:\/\/doi.org\/10.3899\/jrheum.170932","journal-title":"J Rheumatol"},{"key":"533_CR15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, Mcinnes I, Mease P et al (2009) Golimumab, a\u00a0new human tumor necrosis factor alpha antibody, administered every four weeks as a\u00a0subcutaneous injection in psoriatic arthritis: twenty-four week efficacy and safety results of a\u00a0randomized, placebo-controlled study. Arthritis Rheum 60:976\u2013986","journal-title":"Arthritis Rheum"},{"key":"533_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"MS Heiberg","year":"2008","unstructured":"Heiberg MS, Koldingsnes W, Mikkelsen K et al (2008) The comparative one-year performance of anti tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a\u00a0longitudinal, observational, multicenter study. Arthritis Rheum 59:234\u2013240","journal-title":"Arthritis Rheum"},{"key":"533_CR17","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1136\/ard.2007.085951","volume":"67","author":"A Spadaro","year":"2008","unstructured":"Spadaro A, Ceccarelli F, Scrivo R et al (2008) Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis 67:1650\u20131651","journal-title":"Ann Rheum Dis"},{"key":"533_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/rheumatology\/kep423","volume":"49","author":"AA Saad","year":"2010","unstructured":"Saad AA, Ashcroft DM, Watson KD et al (2010) Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxf) 49:697\u2013705","journal-title":"Rheumatology (Oxf)"},{"key":"533_CR19","first-page":"624","volume":"33","author":"K Vlam De","year":"2015","unstructured":"De Vlam K, Boone C, The Prove Study Group A (2015) Treatment adherence, efficacy, and safety of etanercept in patients with active psoriatic arthritis and peripheral involvement in Belgium for 66\u00a0months (PROVE study). Clin Exp Rheumatol 33:624\u2013631","journal-title":"Clin Exp Rheumatol"},{"key":"533_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3899\/jrheum.140685","volume":"42","author":"M Zisapel","year":"2015","unstructured":"Zisapel M, Zisman D, Madar-Balakirski N et al (2015) Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis. J\u00a0Rheumatol 42:73\u201378","journal-title":"J Rheumatol"},{"issue":"2","key":"533_CR21","doi-asserted-by":"publisher","first-page":"e000567","DOI":"10.1136\/rmdopen-2017-000567","volume":"3","author":"LC Coates","year":"2017","unstructured":"Coates LC, Kishimoto M, Gottlieb A et al (2017) Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (csDMARDs) in biologic DMARD (bDMARD)-na\u00efve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1. RMD Open 3(2):e567","journal-title":"RMD Open"},{"key":"533_CR22","doi-asserted-by":"publisher","first-page":"e000181","DOI":"10.1136\/rmdopen-2015-000181","volume":"1","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, Collier DH, Saunders KC et\u00a0al (2015) Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open 1:e181","journal-title":"RMD Open"},{"key":"533_CR23","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB Mcinnes","year":"2015","unstructured":"Mcinnes IB, Mease PJ, Kirkham B et al (2015) Secukinumab, a\u00a0human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a\u00a0randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386:1137\u20131146","journal-title":"Lancet"},{"key":"533_CR24","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB Mcinnes","year":"2013","unstructured":"Mcinnes IB, Kavanaugh A, Gottlieb AB et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780\u2013789","journal-title":"Lancet"},{"key":"533_CR25","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1002\/art.34627","volume":"64","author":"G Schett","year":"2012","unstructured":"Schett G, Wollenhaupt J, Papp K et al (2012) Oral apremilast in the treatment of active psoriatic arthritis: results of a\u00a0multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64:3156\u20133167","journal-title":"Arthritis Rheum"},{"key":"533_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/art.30117","volume":"63","author":"B Glintborg","year":"2011","unstructured":"Glintborg B, Ostergaard M, Dreyer L et al (2011) Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 63:382\u2013390","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0533-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0533-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0533-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T23:18:13Z","timestamp":1568071093000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0533-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0533-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,10]]},"assertion":[{"value":"10 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Dauth, M.\u00a0K\u00f6hm, T.\u00a0Rossmanith, H.\u00a0Burkhardt und F.\u00a0Behrens weisen auf folgende Beziehung hin: Sie erhalten eine Forschungsunterst\u00fctzung von Janssen-Cilag GmbH. E.\u00a0Herrmann und A.\u00a0Lehn geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen wurden mit Zustimmung der zust\u00e4ndigen Ethik-Kommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patienten liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}